- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024kr232.6 (+0.56%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024kr216 (+6.06%)Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023kr211.3 (-3.30%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023kr291.7 (-0.95%)Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023kr254.5 (+8.62%)Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023kr294.7 (-1.96%)Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022kr251.5 (+4.92%)Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022kr79.53 (-2.45%)Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022kr72.68 (-7.86%)Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022kr110.3 (-0.90%)Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021kr142.3 (-1.45%)Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021kr145 (+4.09%)Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021kr91.9 (+3.03%)Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021kr99.68 (-0.45%)Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020kr88.53 (+1.40%)Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020kr79.95 (+6.67%)Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020kr65.3 (-5.64%)Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020kr82.1 (-3.61%)Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019kr90.38Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019kr71.65 (-0.35%)Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019kr74.7 (-0.30%)Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019kr97.22 (+2.22%)Earnings
Q2 2021 BioArctic AB Earnings Call Transcript
Welcome to the BioArctic Q2 Report 2021. Today, I am pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. (Operator Instructions) Speakers, please begin.
()-
Thank you so much. Most welcome to BioArctic's Second Quarter Report for 2021. I'm Gunilla Osswald, and I'm the CEO of BioArctic and I will share the presentation here today with our CFO, Jan Mattsson.
I think it's exciting times for the Alzheimer's community now, both regarding diagnostics with progress of blood biomarkers and also with new therapies. We are most likely on our way towards a paradigm shift for the treatment of Alzheimer's disease. And our most advanced program, lecanemab, previously called BAN2401, was granted breakthrough therapy designation by the FDA in late June. And I will describe more about that in the presentation here today.
Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid-Cap, and this is our disclaimer.
Next slide, please. BioArctic is a unique Swedish
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)